116 results on '"Colado, E."'
Search Results
2. Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world
3. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
4. P631: A PCR-BASED ASSAY FOR IGLV3-21R110 SCREENING CONFIRMS ITS PROGNOSTIC VALUE IN AN INDEPENDENT COHORT OF 613 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
5. P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS
6. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis
7. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
8. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
9. USE OF ZARZIO WITH PLERIXAFOR IN MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS: PH-AB203
10. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty
11. Alternating VAMP/ThaCyDex: An Effective Salvage Regimen in Relapsed Multiple Myeloma Patients: A450
12. BASOPHIL-LINEAGE COMMITMENT IN ACUTE PROMYELOCYTIC LEUKEMIA PREDICTS FOR SEVERE BLEEDING AFTER STARTING THERAPY
13. Tuberculous arachnoiditis after a second allogeneic haematopoietic stem cell transplantation for acute lymphoblastic leukemia in CR2
14. Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma
15. Flow cytometry for the diagnosis of hematolymphoid neoplasms in primary care systems. Role of laboratory decision rules
16. Monocytic subpopulation analysis by multidimensional flow cytometry outperforms classical variables for CMML diagnosis
17. Clonality assessment in suspected cytotoxic T cell lymphoproliferations: To KIR or not to KIR
18. Flow cytometry inmunophenotyping can identify and characterize solid tumour cells in clinical samples: A preliminary study
19. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications
20. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
21. Role of Antimicrobial Prophylaxis in Patients with Higher-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Receiving Azacitidine Therapy
22. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
23. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)
24. 279 - Role of Antimicrobial Prophylaxis in Patients with Higher-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Receiving Azacitidine Therapy
25. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption
26. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
27. P-216 The study of cell chimerism after allogeneic transplantation can improve the management of patients with hematopoietic myeloid malignancies
28. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
29. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
30. A450 Alternating VAMP/ThaCyDex: An Effective Salvage Regimen in Relapsed Multiple Myeloma Patients
31. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
32. Comparison between lymphoglobulin- and thymoglobulin-based immunosuppressive therapy as first-line treatment for patients with aplastic anaemia
33. Optimizing the use of Erythropoietin-Receptor stimulating Agents (ERAs) in patients with hematopoietic malignancies based on the level of reticulocyte hemoglobin | Optimización del uso de Agentes estimulantes del Receptor de la Eritropoyetina (AREs) en pacientes con neoplasias hematológicas basado en el nivel de hemoglobina reticulocitaria
34. Optimizing the use of Erythropoietin-Receptor stimulating Agents (ERAs) in patients with hematopoietic malignancies based on the level of reticulocyte hemoglobin,Optimización del uso de Agentes estimulantes del Receptor de la Eritropoyetina (AREs) en pacientes con neoplasias hematológicas basado en el nivel de hemoglobina reticulocitaria
35. THE STUDY OF CELL CHIMERISM AFTER ALLOGENEIC TRANSPLANTATION CAN IMPROVE THE MANAGEMENT OF PATIENTS WITH HEMATOPOIETIC MYELOID MALIGNANCIES
36. EFFECTIVENESS OF ACTIVE SURVEILLANCE IN THE REDUCTION OF MORTALITY FROM MULTI-RESISTENT GRAM NEGATIVE BACILLI (BGNMR) INFECTION IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
37. Immunologic characterization of COVID-19 patients with hematological cancer
38. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.
39. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study.
40. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.
41. Routine flow cytometry approach for the evaluation of solid tumor neoplasms and immune cells in minimally invasive samples.
42. Cytomegalovirus in Haematological Tumours.
43. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
44. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.
45. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
46. Immunologic characterization of COVID-19 patients with hematological cancer.
47. Development of an algorithm for the identification of leukemic hematolymphoid neoplasms in Primary Care patients.
48. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment.
49. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
50. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.